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Objective: To determine the effects of ovarian stimulation with highly purified urofollitropin on oocyte and
embryo quality.
Design: Parallel randomized open-label clinical study.
Setting: Assisted reproduction centers.
Patient(s): Two hundred sixty-seven infertile couples undergoing IVF/ICSI.
Intervention(s): All participants underwent standard down-regulation with GnRH analogue. One hundred
thirty-three participants received highly purified urinary FSH and 134 controls received recombinant FSH.
Main Outcome Measure(s): Primary end points were number of morphologically mature oocytes retrieved,
embryo quality, and pregnancy and implantation rates. Secondary end points were: total number of days of
FSH stimulation, total dose of gonadotropin administered, fertilization rate per number of retrieved oocytes,
embryo cleavage rate, live birth and miscarriage rates, endometrial thickness and estradiol level on the day of
hCG administration, cancellation rate, and incidence of moderate or severe ovarian hyperstimulation syn-
drome.
Result(s): Pregnancy and implantation rates were nonsignificantly higher in the urinary FSH group than the
recombinant FSH group (46.5% vs. 36.8% and 22.1% vs. 15.8%, respectively). The grade 1 embryo score was
significantly higher in the urinary FSH group than the recombinant FSH (42.1% vs. 33.5%), and the live birth
rate was nonsignificantly higher in the former group.
Conclusion(s): Highly purified urinary FSH is as effective, efficient, and safe for clinical use as recombinant
FSH. (Fertil Steril 2002;78:1061–7. ©2002 by American Society for Reproductive Medicine.)
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Induction of multifollicular growth in as-
sisted reproduction programs is essential for
successful treatment. Since pregnancy and live
birth rates are correlated with the number of
fertilized oocytes (1), IVF procedures have his-
torically used protocols involving administra-
tion of gonadotropins to increase the number of
oocytes available for eventual embryo transfer.
Ovarian stimulation regimens generally in-
clude pituitary desensitization (down-regula-
tion) with a GnRH analogue followed by ad-
ministration of gonadotropins (2). Pituitary
down-regulation with GnRH agonist, which in-
hibits the mid-cycle LH surge, is one of the
most effective ways to induce formation of
enough preovulatory follicles (3–5).
Until recently, gonadotropins used for ovar-
ian stimulation have been extracted from the
urine of postmenopausal women. Since meno-
pausal gonadotropin (hMG) is of human origin,
the source is not consistent and the end product
is always contaminated with 95% non-FSH,
human proteins, and LH (6). Urinary proteins
may negatively affect follicle recruitment and
development (7).
The introduction of highly purified urinary
FSH, which contained95% FSH protein con-
tent and a negligible amount (0.1 per 1,000 IU
of FSH) of LH (8), has substantially addressed
the contamination problem. Some reports have
indicated that use of highly purified FSH has
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resulted in higher pregnancy rates than those obtained with
hMG (9–11).
With the advent of recombinant DNA technology, two
pure FSH preparations have become available: follitropin-
and follitropin-. Recombinant human FSH has a specific
activity of 10,000 IU/mg protein and lacks LH activity or
extraneous human proteins (12–14). Its purity and in vivo
bioactivity are thought to confer safety, efficiency, and tol-
erability advantages over urine-derived FSH (15, 16).
Recent clinical trials have shown that recombinant FSH is
effective in terms of number of oocytes retrieved, number of
embryos obtained, and total gonadotropin dose needed, with-
out increasing the risk for the ovarian hyperstimulation syn-
drome (OHSS) (17–19). In addition, recombinant FSH has
been shown to be as effective as urinary FSH or hMG
(20–24), with or without GnRH agonists. However, in most
of these trials, the main end points were the number of
oocytes retrieved and embryos obtained, dosage and duration
of stimulation, and rates of fertilization, pregnancy, and
implantation.
Few trials have investigated the possible difference be-
tween recombinant FSH and highly purified urinary FSH in
terms of the quality of oocytes and embryos in stimulated
cycles. Recent data show that hMG compares favorably to
recombinant FSH (25, 26) in terms of oocyte and embryo
quality and subsequent pregnancy rates.
We sought to compare the effects of highly purified
urinary FSH and recombinant FSH on oocyte and embryo
quality and on pregnancy and implantation rates.
MATERIALS AND METHODS
Patient Selection
Two hundred sixty-seven infertile couples were recruited
between December 1998 and November 2000. Women 18 to
38 years of age were included if they fulfilled the following
criteria: [1] infertility attributable to tubal factor, male factor,
or unexplained infertility; [2] serum levels of FSH, LH, and
prolactin in the normal range; [3] regular ovulatory men-
strual cycles of 25 to 35 days; [4] a normal uterine cavity; [5]
no treatment with gonadotropins in the month before study
entry; [6] presentation for the first IVF treatment cycle; [7]
body mass index 18 but 26 kg/m2; and [8] willingness to
participate in the study and to comply with the procedures.
Patients were excluded if they had gynecologic abnormal-
ities or disease, previous poor response to gonadotropins
used for IUI, history of severe OHSS, or current polycystic
ovary syndrome or if the male partner had azoospermia or
clinical signs of infection detected in semen analysis within
12 months before treatment.
Patients were extensively counseled about the nature of
the study and gave written informed consent. The Institu-
tional Review Board of each participating center approved
the study.
Study Design
We performed a prospective, open, randomized, parallel-
group study at three hospital-affiliated IVF centers in Italy.
The study was designed to compare the effectiveness of
recombinant FSH (Gonal-F; Serono, Rome, Italy) and highly
purified urinary FSH (Fostimon; AMSA, Rome, Italy) ad-
ministered during a single IVF cycle. Evaluation was based
on the number of mature oocytes and on embryo quality as
a primary end point of the study.
Fostimon is a new preparation of highly purified urinary
FSH obtained by an ion-exchange chromatography column
method. It has a specific activity of 6,000 IU/mg protein
and purity 90%. This high level of biological potency and
purity allows safe administration by intramuscular or subcu-
taneous routes.
All patients underwent standard pituitary down-regulation
with GnRH analogue (triptorelin) (Decapeptyl; Ipsen, Milan,
Italy), 3.75 mg i.m. on day 21 of their cycle. Fifteen days
later, patients were considered desensitized and gonadotro-
pin administration was begun, provided that ultrasonography
showed no follicles 10 mm in diameter, endometrial thick-
ness7 mm, and estradiol serum concentration50 pg/mL.
After pituitary desensitization, patients were randomized
to receive highly purified urinary FSH or recombinant FSH,
administered once daily s.c., starting with a fixed dose of 225
IU/d for the first 6 days. Ovarian response was assessed on
day 6 by ultrasonography and by measurement of serum
estradiol to evaluate whether a change in the dose was
required.
Patients with a poor response to gonadotropin treatment
were withdrawn from the study. Patients with excessive
response were counseled about the risk for OHSS and were
advised to interrupt the stimulation cycle or to undergo
oocyte retrieval with cryopreservation of any resultant em-
bryos for replacement in the subsequent cycle.
Follicle-stimulating hormone was administered daily until
the criteria for triggering final follicular maturation (leading
follicle with a mean diameter 18 mm and at least two other
follicles with a diameter 16 mm) were met. Ovulation was
triggered by i.m. administration of 10,000 IU of hCG 12 to
16 hours after the last ultrasonogram that confirmed ade-
quate follicular development.
Oocytes were retrieved 34 to 36 hours after hCG admin-
istration. The cumulus–oocyte complex was assessed ac-
cording to the oocyte maturation score criteria described by
Veeck (27). The oocytes were then inseminated in vitro by
conventional IVF or ICSI, and the resultant embryos were
scored according to the criteria of Veeck (28).
In brief, embryos were scored on the basis of morpho-
logic appearance and fragmentation. Grade 1 embryos had
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equal-sized blastomeres and no fragmentation; grade 2 em-
bryos had equal-sized blastomeres with minor cytoplasmic
fragmentation; grade 3 embryos had unequal-sized blas-
tomeres with variable fragmentation; grade 4 embryos had
equal- or unequal-sized blastomeres with 10% fragmenta-
tion; grade 5 embryos had equal- or unequal-sized blas-
tomeres and 20% fragmentation; and grade 6 embryos had
few, small blastomeres and severe fragmentation comprising
50% of the embryo surface (28).
Embryos were transferred on day 3 after oocyte retrieval.
No more than three embryos per patient were transferred.
Luteal phase support was initiated on the day of oocyte
retrieval by using a commercially available progesterone
preparation (50 mg/mL i.m.). Surplus embryos were cryo-
preserved. Clinical pregnancy was confirmed 6 weeks after
embryo transfer by ultrasonography.
Efficacy Measures
Primary end points were the number of mature oocytes
retrieved, embryo quality, and clinical pregnancy and im-
plantation rates. Secondary endpoints were total dose of FSH
administered, total number of days of stimulation, serum
estradiol level and endometrial thickness on the day of hCG
administration, fertilization rate, embryo cleavage rate, live
birth and miscarriage rates, cancellation rate, and incidence
of moderate or severe OHSS. All end points except the
cancellation rate, the incidence of OHSS, and the number of
frozen embryos were analyzed statistically.
Statistical Analysis
The t-test, 2 square table of contingency, and analysis of
variance were used where appropriate. Statistical signifi-
cance was established if P.05.
RESULTS
The patients were divided into two groups: One hundred
thirty-three received highly purified FSH (urofollitropin),
and 134 “controls” received recombinant FSH (follitropin-
). Of the 267 randomized patients, 264 completed the cycle
and had oocyte retrieval. Two couples in the urinary FSH
group and one couple in the recombinant FSH group (1.5%
and 0.7% of patients, respectively) were excluded owing to
excessive ovarian response leading to high risk for OHSS.
The two study groups were similar in terms of age, body
mass index, duration of stimulation, number of ampules or
vials of FSH administered, and estradiol level and endome-
trial thickness on day of hCG administration (Table 1).
Table 2 shows oocyte maturity, fertilization rate, and
cleavage rate for all patients who underwent oocyte retrieval.
No significant difference between groups was found for
mean number of oocytes retrieved per patient, average num-
ber of morphologically mature oocytes, and fertilization rate.
The embryo cleavage rate was nonsignificantly lower in the
urinary FSH group than the recombinant FSH group.
The highest proportion of grade 1 embryos occurred in
the urinary FSH group (42.1% vs. 33.5% in the recombinant
FSH group; P.05). The percentages of grade 2, 3, 4, or 5
embryos did not differ statistically between group, whereas
the percentage of grade 6 embryos was significantly lower
(P.05) in the urinary FSH group than the recombinant FSH
group (5.1% vs. 8.5%. respectively) (Table 3).
The rates of clinical pregnancy and implantation were
nonsignificantly higher in the urinary FSH group than in the
recombinant FSH group. However, the live birth rate per
embryo transfer was nonsignificantly higher in the urinary
FSH group than in the recombinant FSH group (56.5% vs.
38.3%). The multiple pregnancy rate was also nonsignifi-
cantly higher in the former group (29.5% vs. 22.4%). Fro-
zen-thawed embryos were not included in this study (Table
4).
DISCUSSION
The recent availability of recombinant FSH has intro-
duced an alternative to urine-derived FSH for ovarian stim-
ulation regimens. Several comparison studies have shown
that recombinant FSH is more effective than urinary FSH
T A B L E 1
Outcome of patients stimulated with highly purified FSH or recombinant FSH.
Characteristic
Highly purified
FSH group
Recombinant
FSH group P value
No. of patients 133 134
Age (y) 32 4 31.8  6 .928
Body mass index (kg/m2) 21.2  2.8 20.6  3 .954
Duration of stimulation (d) 13.4 1.5 13.7  1.4 .869
No. of ampoules or vials of FSH, 75 IU 51.7  15 60.5  21 .591
17-estradiol level on the day of hCG administration (pg/mL) 1,891.6 975.5 1,698.5  864.4 .368
Endometrial thickness on day of hCG administration (mm) 11.5 1.6 11.6  2 .830
Note: Values with the plus/minus sign are the mean (SD).
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(hMG or highly purified FSH) and that the absence of LH
activity in recombinant FSH does not inhibit follicular
growth.
Studies have shown that FSH, even in the absence of LH,
induces multiple follicular growth as well as meiotically and
developmentally competent oocytes (17), although serum
concentrations of estradiol remain lower than levels resulting
from follicular stimulation with hMG (29–33). However, in
agreement with our results, recent studies of urinary FSH or
hMG and recombinant FSH had similar results in terms of
oocyte and embryo quality and of implantation and preg-
nancy rates (25, 26, 34).
We aimed to compare highly purified FSH with recom-
binant FSH to evaluate possible differences in oocyte and
embryo quality and in implantation and pregnancy rates.
Highly purified FSH proved to be as effective and safe as
recombinant FSH for inducing growth of multiple follicles in
stimulation regimens. Subcutaneous administration of highly
purified FSH had no side effects and was well tolerated, as
reported in previous studies (35, 36).
Recombinant FSH contains a higher proportion of the less
acidic isoforms (isoelectric point range of 3.5 to 6.1),
whereas urinary FSH containing both acidic and mid-acidic
isoforms (isoelectric point range of 3.5 to 5.2). It has been
suggested that the less acidic isoforms have faster circulatory
clearance and, thus, a shorter circulatory half-life (37) than
the acidic isoforms (38, 39). A more recent study has shown
that the slow clearance of the acidic isoform results in better
follicular maturation and estradiol secretion than the less
acidic isoform (40). Further investigation into the role of
FSH isoforms in the modulation and regulation of follicular
growth and maturation is needed.
In our study, the mean number of retrieved oocytes (8.7
3.4 vs. 8.9 4.7) and the number of morphologically mature
oocytes (7.4  1.8 vs. 7.7  3.2) did not differ between the
urinary FSH group and the recombinant FSH group. Of note,
the serum estradiol level on the day of hCG administration
was nonsignificantly higher in the urinary FSH group than in
the recombinant FSH group (1,891  975.5 pg/mL vs.
1,698.5  864.4 pg/mL). These findings contrast with those
of some previous studies (18, 19, 41) but agree with those of
Jacob et al. (42), who found a significantly lower estradiol
level in the recombinant FSH group than the urinary FSH (or
hMG) group. This observation might be explained by the
fact that LH is required for normal steroidogenesis activity
during follicular growth while increasing the number of FSH
receptors on granulosa cells (43). Alternatively, the negligi-
ble amount of LH in highly purified urinary FSH may affect
estrogen production (22, 42).
Patients treated with urinary FSH had a statistically
higher number of grade 1 embryos than did patients treated
with recombinant FSH group (42.1% vs. 33.5%; P.05), but
the number of morphologically mature oocytes was similar
in the two groups. The number of grade 2, 3, 4, and 5
embryos was similar in both groups, whereas the number of
grade 6 embryos was statistically lower in the urinary FSH
group. These differences may reflect the slightly higher
T A B L E 2
Oocyte maturity and fertilization and cleavage rates in patients stimulated with highly purified FSH or recombinant FSH.
Characteristic
Highly purified
FSH group
Recombinant
FSH group P value
No. of patients with oocyte retrieval 131 133
No. of retrieved oocytes 1,146 1,197 .878
Mean  SD 8.7 3.4 8.9  4.7
No. of morphologically matured oocytes (%) 978 (85.3) 1,029 (86) .804
Mean  SD 7.4 1.8 7.7  3.2
No. of two-pronuclei oocytes (%) 741 (64.6) 788 (65.8) .766
Mean  SD 5.7 1.7 5.9  2
Cleaved embryos (%) 589 (79.5) 668 (84.7) .449
Note: Values with the plus/minus sign are the mean (SD).
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T A B L E 3
Embryo score after stimulation with highly purified FSH or
recombinant FSH.
Embryo scorea
Highly purified
FSH group
Recombinant
FSH group P value
Grade 1 (%) 248 (42.1) 224 (33.5) .05
Grade 2 (%) 183 (31) 203 (30.4) .887
Grade 3 (%) 59 (10) 86 (12.9) .186
Grade 4 (%) 40 (6.8) 63 (9.4) .142
Grade 5 (%) 29 (5) 35 (5.3) .910
Grade 6 (%) 30 (5.1) 57 (8.5) .05
a The embryos were scored according to the criteria established by Veeck
(1988).
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pregnancy and implantation rates in patients treated with
urinary FSH compared with recombinant FSH (46.5% vs.
36.8% and 22.1% vs. 15.8%, respectively). The slightly
lower miscarriage rates and higher live birth rates in the
urinary FSH group may indicate that urinary FSH has a
better effect on embryo quality.
The rate of pregnancy, implantation, and live birth may
not have differed significantly between the groups because
of small sample. Assuming that the difference between re-
combinant FSH and urinary FSH is 5%, at least 1,212
participants for each group would be needed to reach 90%
power and an  value of .05. However, our study has a
statistical power of 15% to 20%.
Of the factors that affect oocyte quality in stimulated
cycles, the most important appear to be patient age, basal
FSH concentration, profound suppression of LH during
down-regulation, and estradiol concentration per growing
follicle. Estradiol and androgens are reported to affect oocyte
nuclear maturation and fertilization and may contribute to
embryo development (44–47).
Profound suppression of LH during the down-regulation
protocols generally used for ovarian stimulation negatively
affects treatment outcome (48–50). Recent studies demon-
strated that low concentrations of endogenous LH (3 mIU/
mL) in the late follicular phase of an IVF cycle are associ-
ated with significantly lower fertilization rates and higher
biochemical pregnancy rates. The authors suggested that
when using recombinant FSH only, it may be of clinical
benefit to add LH in the late follicular phase or to further
reduce the dose of GnRH analogue (48, 51).
Conversely, recombinant FSH is reported to be more
effective than urinary FSH for ovarian stimulation, even
when used in combination with a long-acting GnRH agonist
(depot formulation) (20, 29, 52). Loumaye et al. (53) re-
ported that patients with very suppressed serum LH levels
respond similarly to those with moderately suppressed LH
levels and that about 60% of patients might benefit from a
more pronounced pituitary down-regulation, whereas only
less than 6% of patients would benefit from exogenous LH
administration (53).
Although LH plays an important role during ovarian
stimulation (44), excessive LH during the follicular phase
has been shown to have a detrimental effect on oocyte
quality and thus fertility (54). However, other studies found
that an elevated LH level on the day of hCG administration
in a low-GnRH analogue protocol does not reduce cycle
fecundity (55). These discrepant findings require further
investigation. In a recent study, hMG (1:1 FSH/LH) pro-
duced comparable results to recombinant FSH when used
alone for ovarian stimulation (25, 26, 56).
We conclude that highly purified FSH is as effective as
recombinant FSH for ovarian stimulation protocols, thus
offering a viable alternative to recombinant FSH.
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